Predicted to enable chromatin binding activity and transcription corepressor activity. Predicted to be involved in several processes, including positive regulation of proteasomal ubiquitin-dependent protein catabolic process; regulation of generation of precursor metabolites and energy; and response to hypoxia. Predicted to act upstream of or within granulocyte differentiation and negative regulation of transcription by RNA polymerase II. Predicted to be located in nucleoplasm. Predicted to be active in nucleus. Orthologous to human CBFA2T3 (CBFA2/RUNX1 partner transcriptional co-repressor 3).
RGD Description
Predicted to enable chromatin binding activity and transcription corepressor activity. Predicted to be involved in several processes, including negative regulation of DNA-templated transcription; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; and regulation of generation of precursor metabolites and energy. Predicted to act upstream of or within granulocyte differentiation and negative regulation of transcription by RNA polymerase II. Predicted to be located in nucleoplasm. Predicted to be active in nucleus. Orthologous to human CBFA2T3 (CBFA2/RUNX1 partner transcriptional co-repressor 3); INTERACTS WITH 17alpha-ethynylestradiol; 2,3,7,8-tetrachlorodibenzodioxine; acetamide.